Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PAFSC 2nd Committee Endorses Approval of AZ’s Vandetanib
August 5, 2015
- Lupus Nephritis to Be Added to Cellcept’s Indication: MHLW Notification
August 4, 2015
- PAFSC’s First Committee Supports Approval of Actelion’s Tracleer for Digital Ulcers in Generalized Scleroderma
August 3, 2015
- AMED Sets Up 5-Step Process to Pick Licensees of Academic Drug Seeds
July 30, 2015
- MHLW to Continue Discussions on Elderly Use of Prevenar 13 under National Vaccination Program
July 29, 2015
- Finance Minister Calls for Revision of Special Measures on Taxation “Without Preconceptions”
July 28, 2015
- Government Approves Basic Policy on Budget Requests for FY2016
July 28, 2015
- ICH Assembly to Make Final Decisions on All Important Issues: PMDA Official
July 27, 2015
- Japan Embarking on Biosimilar Development, but It’s a Race against Time: MHLW Official
July 24, 2015
- Japan Eyes Linking Dormant Pricing Premium with Sakigake System, Upping Rate to 20% at Maximum
July 24, 2015
- Chuikyo Subcommittee OKs Plan to Draft GL for Analyzing Cost-Effectiveness; QALY Expected to Be Main Index
July 24, 2015
- Drug Pricing Organization Proposes Re-Pricing of Products with Huge Sales
July 23, 2015
- Kaketsuken Withdraws Earlier Explanation of Blood Products Scandal; Problem Discovered through Information Provided to MHLW
July 23, 2015
- AMED Takes Initial Step Toward Out-Licensing First Lead Compound; Now Taking Applications from Companies
July 23, 2015
- PMDA Calls for Caution for Use of Inavir, Relenza in Patients Allergic to Milk Products
July 23, 2015
- MHLW Raises Flag on Vaccine Expiration Dates after Imovax Polio Mishaps
July 22, 2015
- MHLW Panel OKs Shipment of 2 Kaketsuken Blood Products
July 22, 2015
- Govt Sets FY2016 Budget Allocation Policy for Healthcare R&D
July 22, 2015
- Z2 Rule, DPC Incentive Need Revisions in Line with New Generic Target: MOF Budget Examiner
July 22, 2015
- Second Committee on Drugs to Discuss Approval of AZ’s Vandetanib at Meeting on Aug. 3
July 22, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…